Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.39 |
| ▸ | FAP | Q12884 | 4/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6241044 | 1.00 | DPP4 (0.39) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL30369668 | 1.00 | DPP4 (0.39) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL27179173 | 0.81 | MAPT (0.41) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3874305 | 0.81 | DPP4 (0.56) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL1154736 | 0.81 | DPP4 (0.56) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3397659 | 0.81 | DPP4 (0.56) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL25505409 | 0.79 | TSHR (0.43) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL6238139 | 0.78 | ATM (0.40) | DPP4DPP8DPP9 | |
| SCHEMBL6235358 | 0.78 | ATM (0.40) | DPP4DPP8DPP9 | |
| SCHEMBL31298379 | 0.78 | ATM (0.40) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101557-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | INCYTE CORPORATION | 2024-03-28 | — | — | US | disclosed |
| US-11939328-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | DPP4 3819/4885FAP 1595/4885DPP8 3103/4885 |
| US-20240101557-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | KRAS, NRAS, HRAS | DPP4 3994/4885FAP 420/4885DPP8 2650/4885 |
| US-11939328-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | DPP4 3819/4885FAP 1595/4885DPP8 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.